Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Pfizer : Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 31781) - Meeting

share with twitter share with LinkedIn share with facebook
share via e-mail
07/17/2017 | 07:16pm CET

TIME: 8 a.m.

EVENT: Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 31781) holds a meeting of the Arthritis Advisory Committee to discuss supplemental new drug applications 203214 supplement 17, for XELJANZ (tofacitinib) tablets and 208246 supplement 3, for XELJANZ XR (tofacitinib) extended release tablets submitted by Pfizer Inc., for the treatment of adult patients with active psoriatic arthritis.

DATE: August 3, 2017

LOCATION: FDA White Oak Campus, 10903 New Hampshire Avenue, Building 31 Conference Center, the Great Room, Room 1503, Silver Spring, Md.

CONTACT: Philip Bautista, 301-796-9001, AAC@fda.hhs.gov

(c) 2006 Federal Information & News Dispatch, Inc., source Washington Daybook

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on PFIZER
03:11p PFIZER : The USA’s Musculoskeletal Drugs Market To Fall As A Share Of The ..
09:32a PFIZER : ViiV Healthcare`s two-drug regimen, Juluca receives US FDA approval for..
11/23 PFIZER : ViiV Healthcare announces US FDA approval for Juluca
11/23 PFIZER : GSK group of companies - Juluca approved in US as first 2-drug regimen,..
11/23 RESEARCHERS AT WASHINGTON UNIVERSITY : DiviTum® can evaluate the biologic activi..
11/22 PFIZER : demands return of drugs set for use in US lethal injections
11/22 U.S. FDA approves first two-drug HIV regimen in win for GSK
11/22 PFIZER : Juluca® (dolutegravir and rilpivirine) approved in US as first 2-drug r..
11/21 PFIZER : Data on Clinical Research Detailed by Researchers at Pfizer (mTORC1 sti..
11/21 PFIZER : New Biochemistry Findings from Pfizer Described (Microfluidic-Enabled I..
More news
News from SeekingAlpha
11/22 Cabozantinib Franchise Will Continue To Transform Exelixis' Fortunes In 2018
11/22 THE NEXT BILLION DOLLAR BLOCKBUSTER : Why Value Investors Should Look At Omeros ..
11/22 YOUR DAILY PHARMA SCOOP : Teva Valuation, DelMar Lead Candidate, Galapagos Comme..
11/22 Mystery Stocks Revealed In My 88 Stock Portfolio Along With 2018 Income Estim..
11/22 Trading Quality Stocks And Short Term Rates Higher Update
Financials ($)
Sales 2017 52 541 M
EBIT 2017 19 883 M
Net income 2017 10 977 M
Debt 2017 23 944 M
Yield 2017 3,61%
P/E ratio 2017 18,95
P/E ratio 2018 16,46
EV / Sales 2017 4,48x
EV / Sales 2018 4,34x
Capitalization 211 B
Duration : Period :
Pfizer Technical Analysis Chart | PFE | US7170811035 | 4-Traders
Technical analysis trends PFIZER
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 38,2 $
Spread / Average Target 7,7%
EPS Revisions
Ian C. Read Chairman & Chief Executive Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Dennis Arthur Ausiello Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER9.08%211 188
JOHNSON & JOHNSON19.17%368 832
NOVARTIS12.82%222 846
ROCHE HOLDING LTD.6.15%216 979
MERCK AND COMPANY-7.64%148 286
AMGEN16.24%123 376